RESUMO
This work presents a method to characterize high molecular esters in beeswax and resinous substances based on the use of microwave-assisted extraction and flow injection analysis-high resolution mass spectrometry that combines the high efficiency of the extraction procedure with the advantages of high resolution mass spectrometry. This approach allows us to identify archaeological beeswax and plant resinous substances by the characterization of the survived intact high molecular weight components. By this way, several raw materials (beeswax, pine resin and pitch, and resin extracted from Euphorbia tirucalli) were studied and used as reference substances. The procedure was then tested on an adhesive dated 44-42 ka BP recovered from Border Cave (KwaZulu-Natal, Africa), allowing us to detect the high molecular weight species even after almost 50,000 years, and then used to chemically investigate unknown archaeological adhesives from Antinoopolis (Egypt), dated to the 4th-5th century AD. The results allowed us to extend our knowledge on the long-term behavior of beeswax and resinous substances.
RESUMO
Presentamos un paciente con Lupus Eritematoso Sistémico (LES) tratado previamente con Rituximab y Micofenolato Mofetilo que desarrolló una criptococosis meníngea. Los pacientes con LES presentan múltiples defectos en su sistema inmune (SI) que, sumados a los producidos por los tratamientos inmunosupresores, predisponen a infecciones, entre ellas, a las causadas por gérmenes oportunistas. La meningitis por criptococo es una rara y severa complicación en estos pacientes. Rituximab produce una serie de cambios en el SI actuando sobre los linfocitos B, mientras que micofenolato actúa tanto sobre las células T como B. Las alteraciones inmunológicas presentes en nuestro paciente serían producto de la sumatoria de efectos de ambas drogas que explicarían la infección por Criptococcus neoformans.
We presented a systemic lupus erythematosus (SLE) patient previously treated with rituximab and mycophenolate who developed cryptococcal meningitis. SLE patients have multiple defects in the immunity system in addition to the additive effects of immunosuppressive treatments, which predispose to opportunistic infections. Cryptococcal meningitis is a rare and severe complication in SLE patients. Rituximab produces a series of changes in the immune system by acting on B cells, while mycophenolate produces its actions by acting on T and B cells. The immunology system defects in our patient could be done because the additive effects of two drugs that could explain the Cryptococcus neoformans infection.
